Tourmaline Bio (TRML) announced positive topline results from its ongoing Phase 2 TRANQUILITY trial evaluating quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein (hs-CRP), a biomarker associated with elevated cardiovascular risk, and chronic kidney disease. The TRANQUILITY trial is the starting point of Tourmaline’s clinical development program for pacibekitug for the potential treatment of atherosclerotic cardiovascular disease and other cardiovascular diseases. Tourmaline continues to make progress in advancing the clinical development strategy for pacibekitug in cardiovascular inflammation and assessing potential Phase 3 trial designs in patients with ASCVD. Additionally, Tourmaline plans to initiate a Phase 2 proof-of-concept trial in patients with abdominal aortic aneurysm in the second half of 2025
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Buy Rating for Tourmaline Bio: Anticipated Catalyst from Phase 2 TRANQUILITY Study on Pacibekitug
- Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating
- Tourmaline Bio’s Promising Clinical Developments and Strategic Expansion Drive Buy Rating
- Tourmaline Bio Reports Q1 2025 Financial Results
- Tourmaline Bio’s Promising Clinical Trials and Strong Financial Position Justify Buy Rating